Optimizing HRRm Testing and Workflow Integration in mCSPC
Pfizer
UM Funding ID
FD04205
Sponsor
Pfizer
Category
Canadian Funding Opportunities
Description
This competitive program seeks to address key challenges in HRRm testing (e.g. germline, tissue, or circulating tumour DNA (ctDNA) approaches) in the metastatic castration-sensitive prostate cancer (mCSPC) setting or enhance coordination and workflow integration across these modalities via quality improvement (implementation science) or research.
Individual projects requesting 20,000 CAD to 100,000 CAD will be considered.
VPRI Contact
Heather Martin
Research Contracts Officerheatherdarlene [dot] .martin [at] @umanitoba [dot] .ca
Deadlines
| UM Internal Deadline (to ADR) | Sponsor Deadline | |
|---|---|---|
Application | 18-Mar-2026 | 08-Apr-2026 |
Important
The information in this directory is provided as a service to the University Community and anyone with legitimate business with the University. Use of this directory to prepare mass mailings is prohibited.